Novocure Ltd
Atidarymo kaina
SektoriusSveikatos priežiūra
17.53 -1.41
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
17.43
Max
18.27
Pajamos | -47M -71M |
|---|---|
Pardavimai | -295K 174M |
Pelnas, tenkantis vienai akcijai | -0.62 |
Pelno marža | -40.871 |
Darbuotojai | 1,605 |
EBITDA | -29M -63M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +46.23% upside |
Kitas uždarbis | 2026-07-23 |
|---|
Rinkos kapitalizacija | 506M 2B |
|---|---|
Ankstesnė atidarymo kaina | 18.94 |
Ankstesnė uždarymo kaina | 17.53 |
Naujienos nuotaikos
By Acuity
50%
50%
146 / 342 reitingas Healthcare
Novocure Ltd Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.